Navigation Links
Octapharma Targets Primary Immune Deficiency Research With Grant for The Mount Sinai Medical Center
Date:1/18/2011

NEW YORK and HOBOKEN, N.J., Jan. 18, 2011 /PRNewswire/ -- Octapharma USA today announced the second grant recipient of the Octapharma 25th Anniversary Grants Program is the Clinical Immunology Research Laboratory at The Mount Sinai Medical Center. The Octapharma Grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine.

Charlotte Cunningham-Rundles, M.D., Ph.D., Director of the Allergy Immunology and the Immunology Training Program and Director of the Immunodeficiency Clinic at The Mount Sinai Medical Center, is the lead investigator for a research project focused on distinguishing true Common Variable Immune Deficiencies (CVID) from disorders with more modest immune defects. Dr. Cunningham-Rundles has nearly 30 years experience with clinical immune deficiency disorders with a research focus of human immunodeficiency diseases and immuno-reconstitution.

Octapharma AG, one of the largest human protein products manufacturers in the world, launched the Octapharma Grants program last year in celebration of the biopharmaceutical company's 25th anniversary. The company's first ever grants program is only available to researchers based in the United States and is administered by Octapharma USA, the Swiss company's U.S. subsidiary.

"It is a pleasure to announce Octapharma's support for the valuable research being pursued by the Clinical Immunology Research group at The Mount Sinai Medical Center," said Octapharma USA President Flemming Nielsen. "Dr. Cunningham-Rundles is a well-recognized national leader in the field of clinical and laboratory immunology and we consider her research extremely important in understanding how to best diagnose and treat primary immune deficiency earlier and more effectively. The grant program and its second award will continue to advance Octapharma's firm commitment to the U.S. market, underscoring our commitment to provide patients with the safest, highest quality therapies available today."

CVID is a primary immune defect characterized by poor or absent production of immune globulins IgG, IgA and/or IgM. CVID is a type of primary immune deficiency disease with high clinical interest due to its prevalence, severity of complications, rate of hospitalizations and necessity for lifelong immune globulin therapy.  Unfortunately, using the available published criteria for diagnosing CVID, physicians have difficulty distinguishing this disease from milder immune defects of antibody production.  The difficulty of distinguishing between patient groups is medically important as subjects with validated CVID appear more likely to develop selected inflammatory complications which may require additional monitoring or treatment. Patients with more modest defects may be more exempt from these issues and could require different clinical surveillance.

"The aim of our research is to provide the medical community and patients with information and tools to distinguish the more clear cases of CVID from other milder antibody disorders," said Dr. Cunningham-Rundles. "By reviewing and analyzing clinical records and available laboratory data, we will work toward the development of a scoring system as a clinical tool.  With the large cohort of patients seen at The Mount Sinai Medical Center, the study may be able to determine if the immunologic and clinical differences seen in various defects can be distinguished."

The Octapharma Grants Committee has officially closed the second cycle of 2010 grant applications and has opened the first cycle for 2011 applications.  The deadline for the next cycle of 2011 submissions is March 31. Please visit www.octapharmagrants.com for a complete description of the grants program.

About the Octapharma Group

Headquartered in Lachen, Switzerland, Octapharma AG is one of the largest human protein products manufacturers in the world and has been committed to patient care and medical innovation for over 27 years. Octapharma's core business is the development, production and sale of high quality human protein therapies from both human plasma and human cell-lines, including immune globulin intravenous (IGIV). In the U.S., Octapharma's IGIV product, octagam®  (immune globulin intravenous [human] 5%), is used to treat disorders of the immune system, and Octapharma's Albumin (human)® is indicated for the restoration and maintenance of circulating blood volume. Octapharma's wilate® received orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for the treatment of von Willebrand disease (VWD). Octapharma employs over 4,000 people and has biopharmaceutical experience in 80 countries worldwide, including the United States, where Octapharma USA is located in Hoboken, N.J.  Octapharma operates two state-of-the-art production sites licensed by the FDA, providing a high level of production flexibility. For more information, please visit www.octapharma.com.

About the Clinical Immunology Research Laboratory, The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses both The Mount Sinai Hospital and Mount Sinai School of Medicine. Established in 1968, Mount Sinai School of Medicine is one of few medical schools embedded in a hospital in the United States. The Mount Sinai Medical Center has one of the largest programs in the country for treating patients with antibody defects, treating adult and pediatric patients from throughout the Northeast. The Clinical Immunology Research Laboratory focuses on the investigation of human immunodeficiency diseases and immuno-reconstitution and has been supported by research grants from U.S. Food and Drug Administration (FDA) and the National Institutes of Health (NIH).


'/>"/>
SOURCE Octapharma USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
2. Octapharma Accepting Applications for Research Grants Focused on Human Protein Therapies
3. Octapharma USA Launches Web Resource for von Willebrand Disease Healthcare Professionals and Patients
4. FDA Confirms Orphan Drug Exclusivity Approval for wilate®, Octapharma USAs New Therapy for Common Inherited Bleeding Disorder
5. Octapharma USA Announces Availability and Distributors for wilate®, the First Replacement Therapy Developed Specifically for von Willebrand Disease
6. Octapharma Receives Orphan Drug Exclusivity Approval for wilate(R) - A Replacement Therapy Developed Specifically for von Willebrand Disease
7. Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease
8. Octapharma Group and Fresenius Kabi Enter Into an Exclusive License, Development and Supply Agreement for a HESylated Recombinant Protein
9. Octapharma Targeting the Major Risk of Hemophilia Treatment - FVIII Antibodies
10. Octapharma Accepting Applications for Research Grants on Immunotherapy, Coagulation Disorders and Critical Care
11. Plasma Products Safe Despite Swine Influenza Outbreak, Assures International Biopharmaceutical Company Octapharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... NEW YORK , April 19, 2017 Cardiology ... during the projected period The Cardiology Devices segment ... more than US$ 15 Mn in 2018 over 2017. By ... reach a market valuation close to US$ 700 Mn, expanding ... Cardiology Devices segment dominated the Asia Pacific ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... Global Prostate Cancer Therapeutics Market: Overview ... cancer therapeutics market analyzes the current and future ... prostate cancer, launch of promising emerging therapies, as ... drugs & therapeutic biological products, and high growth ... side effects are some of the drivers expected ...
Breaking Medicine Technology:
(Date:4/24/2017)... ... April 24, 2017 , ... Ridgecrest Herbals makes it a ... new strategies to reduce waste, and support renewable energy. They believe this is a ... nature to find solutions for health issues, and maintain that destroying the environment in ...
(Date:4/24/2017)... ... April 24, 2017 , ... The California Dental Association Foundation’s two-day volunteer dental ... 1,961 people during the April 22-23 event at the San Mateo Event Center. ... barriers to care, CDA Cares educates the public and policymakers about the importance of ...
(Date:4/24/2017)... McLean, Virginia (PRWEB) , ... April 24, 2017 ... ... have announced that they are seeking public support to bring their novel lifesaving ... in appearance, wearable device packed with medical-grade sensors, specially designed to read a ...
(Date:4/24/2017)... ... April 24, 2017 , ... In 2017, ... diagnosed globally; approximately 25,000 of them will be malignant.(1) As research into precision ... type of healthcare model in the diagnosis and treatment of brain tumors. Healthcare ...
(Date:4/24/2017)... ... April 24, 2017 , ... Come to PAINWeekEnd (PWE) ... Jim Walter Blvd, for an educational and exciting 2-day program. , An attendee ... hearing this before they approach patients” about the course entitled Ain't Misbehavin': Decreasing and ...
Breaking Medicine News(10 mins):